The second analysis showed that while no specific antipsychotic offered greater cognitive benefit, first-generation dopamine blockers fared worse for preserving attention, concentration, and memory.

The markups helped the pharmacy-benefit managers reap $7.3 billion from 2017 to 2022, the FTC found.

The Center for Health Information and Analysis would be authorized to collect data on PBMs and issue regulations to better collect information from them and to help the state understand cost ...

Starting Jan. 1, the redesigned drug benefit will operate more like other private insurance policies. Coverage begins after patients pay a deductible, which will be no more than $590 next year.

Pharmaceutical Strategies Group (“PSG”), an EPIC company, published its 2025 Trends in Drug Benefit Design Report, delivering critical insights into how payers are navigating a rapidly ...

After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. drug cost watchdog has provided a final analysis that includes a ...

MA lawmakers send Healey bill to cap some drug costs, regulate pharmacy benefit ... share any of the cost of a generic drug, ... for Pharmaceutical Policy and Analysis within the Health ...

The difference between the AWP cost of a drug and the cost of that same drug on the NADAC can be significant. For example, a generic drug may have an AWP price of $100 but a NADAC price of $15.

Cost–benefit analysis offers a clearer way to communicate the magnitude of costs saved ... cost-effectiveness of hepatitis C testing in Canada,54, 56, 57 and obtained hepatitis C treatment costs from ...